THE COST-EFFECTIVENESS OF SELECTIVE INTERNAL RADIATION THERAPY (SIRT) FOR TREATING ADVANCED UNRESECTABLE HEPATOCELLULAR CARCINOMA IN THE UNITED KINGDOM

被引：0
|
作者：
Walton, M. [1 ]
Claxton, L. [1 ]
Sharif-Hurst, S. [1 ]
Wade, R. [1 ]
Eastwood, A. [1 ]
Hodgson, R. [1 ]
机构：
[1] Univ York, York, Yor, England
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
MT4
引用
收藏
页码：S406 / S406
页数：1
相关论文
共 50 条
  • [31] Clinical and Laboratory Toxicity After Selective Internal Radiation Therapy (SIRT) Using Yttrium-90 Resin Microspheres for Unresectable Hepatocellular Carcinoma
    Gabrielson, A.
    Banovac, F.
    Kim, A.
    Unger, K. R.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E151 - E151
  • [32] Cost-effectiveness analysis of cabozantinib as second-line therapy in advanced hepatocellular carcinoma
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Zhu, Guiqi
    Wu, Qiuji
    Wen, Feng
    Bai, Liangliang
    Li, Qiu
    LIVER INTERNATIONAL, 2019, 39 (12) : 2408 - 2416
  • [33] Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
    Sieg, Maximilian
    Hartmann, Michael
    Settmacher, Utz
    Arefian, Habibollah
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [34] Comparative cost-effectiveness of cabozantinib as second-line therapy for patients with advanced hepatocellular carcinoma in Germany and the United States
    Maximilian Sieg
    Michael Hartmann
    Utz Settmacher
    Habibollah Arefian
    BMC Gastroenterology, 20
  • [35] Cost-effectiveness of Sorafenib for Treatment of Advanced Hepatocellular Carcinoma in India
    Gupta, Nidhi
    Verma, Rohan K.
    Prinja, Shankar
    Dhiman, Radha K.
    JOURNAL OF CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 9 (04) : 468 - 475
  • [36] Cost-effectiveness of regorafenib in the treatment of advanced hepatocellular carcinoma in Canada
    Hussain, Salman
    Singh, Ambrish
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 382 - 382
  • [37] Cabozantinib for patients with advanced hepatocellular carcinoma: a cost-effectiveness analysis
    Shlomai, Amir
    Leshno, Moshe
    Goldstein, Daniel A.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2019, 12
  • [38] COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA
    Kim, J.
    Hay, J. W.
    VALUE IN HEALTH, 2018, 21 : S29 - S29
  • [39] Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.
    Patel, Kishan
    Stein, Stacey
    Luther, Janki
    Huntington, Scott F.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma
    Ricke, Jens
    Klumpen, Heinz Josef
    Amthauer, Holger
    Bargellini, Irene
    Bartenstein, Peter
    de Toni, Enrico N.
    Gasbarrini, Antonio
    Pech, Maciej
    Peck-Radosavljevic, Markus
    Popovic, Peter
    Rosmorduc, Olivier
    Schott, Eckart
    Seidensticker, Max
    Verslype, Chris
    Sangro, Bruno
    Malfertheiner, Peter
    JOURNAL OF HEPATOLOGY, 2019, 71 (06) : 1164 - 1174
12345